The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer by Munkley, Jennifer et al.
                          Munkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou,
Y., ... Elliott, D. J. (2015). The androgen receptor controls expression of the
cancer-associated sTn antigen and cell adhesion through induction of
ST6GalNAc1 in prostate cancer. Oncotarget, 6(33), 34358-74. DOI:
10.18632/oncotarget.6024
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.18632/oncotarget.6024
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Impact Journals at
http://dx.doi.org/10.18632/oncotarget.6024.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Oncotarget34358www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 33
The androgen receptor controls expression of the cancer-
associated sTn antigen and cell adhesion through induction of 
ST6GalNAc1 in prostate cancer
Jennifer Munkley1, Sebastian Oltean2, Daniel Vodák3, Brian T. Wilson1, Karen E. 
Livermore1, Yan Zhou5, Eleanor Star2, Vasileios I. Floros1, Bjarne Johannessen6, 
Bridget Knight7, Paul McCullagh8, John McGrath9, Malcolm Crundwell10, Rolf I. 
Skotheim6, Craig N. Robson11, Hing Y. Leung5,12, Lorna W. Harries13, Prabhakar 
Rajan5,12, Ian G. Mills14,15,16 and David J. Elliott1
1 Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK
2 Microvascular Research Laboratories, School of Physiology and Pharmacology, University of Bristol, Bristol, UK
3 Bioinformatics Core Facility, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University 
Hospital, Oslo, Norway
4 Northern Genetics Service, Newcastle Upon Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK
5 Beatson Institute for Cancer Research, Glasgow, UK
6 Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
7 NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
8 Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
9 Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
10 Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
11 Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK
12 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
13 Institute of Biomedical and Clinical Sciences, University of Exeter, Devon, UK
14 Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), University of Oslo and Oslo University  
 Hospitals, Oslo, Norway
15 Departments of Molecular Oncology, Institute of Cancer Research and Radium Hospital, Oslo, Norway
16 PCUK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology (CCRCB), 
Queen’s University, Belfast, UK
Correspondence to: Jennifer Munkley, email: Jennifer.munkley@ncl.ac.uk
Keywords: androgens, prostate cancer, ST6GalNAc1, glycosylation, Sialyl-Tn (sTn)
Received: September 02, 2015 Accepted: September 09, 2015 Published: October 07, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Patterns of glycosylation are important in cancer, but the molecular mechanisms 
that drive changes are often poorly understood. The androgen receptor drives 
prostate cancer (PCa) development and progression to lethal metastatic castration-
resistant disease. Here we used RNA-Seq coupled with bioinformatic analyses 
of androgen-receptor (AR) binding sites and clinical PCa expression array data 
to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in 
PCa cells. ST6GalNAc1 encodes a sialytransferase that catalyses formation of the 
cancer-associated sialyl-Tn antigen (sTn), which we find is also induced by androgen 
exposure. Androgens induce expression of a novel splice variant of the ST6GalNAc1 
protein in PCa cells. This splice variant encodes a shorter protein isoform that is still 
fully functional as a sialyltransferase and able to induce expression of the sTn-antigen. 
Surprisingly, given its high expression in tumours, stable expression of ST6GalNAc1 
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INTRODUCTION
Prostate cancer (PCa) development and progression 
is driven by the androgen receptor (AR). Androgen 
deprivation therapy (ADT) is the first line of treatment 
for PCa, and although it is usually initially effective, 
the recurrence of castrate resistant PCa (CRPCa) is 
common and ultimately lethal. Progression to CRPCa 
is thought to involve persistence of AR signalling and 
reprogramming of the AR transcriptional landscape [1, 
2]. Androgen-regulated genes have been identified by 
genome/transcriptome-wide analyses of AR binding 
sites and downstream changes in gene expression in 
response to androgen exposure. The identified genes 
have included regulators of cell cycle, biosynthetic and 
glycolysis pathways, and the master regulators thereof, 
such as calcium/calmodulin-dependent protein kinase 2 
(CAMKK2) [3].
Given the importance of metastasis in PCa mortality, 
a key objective is to identify mechanisms that contribute 
to cell adhesion and migration. Changes in cell surface 
glycosylation are commonly observed during malignancy 
with frequent over-expression of sialylated antigens [4-
6]. A well-known cancer-associated glycan structure is a 
short O-glycan containing a sialic acid residue known as 
sialyl-Tn (sTn) antigen. sTn is synthesised by the enzyme 
ST6GalNAc1 which catalyses transfer of a sialic acid 
in ɑ2-6 linkage onto the Tn antigen (GalNAca1-OSer/
Thr), and modifies the glycosylation pattern of various 
membrane O-glycoproteins [7]. The cellular expression 
status of glycan structures is critical for cell adhesion, 
invasion and metastasis. In PCa the glyco-phenotype of 
transformed cells often becomes modified with a sharp rise 
in sialylation of O-glycans [8]. 
Although patterns of glycosylation change in 
cancer, the underlying mechanisms driving these changes 
are not well understood. Here, we use RNA-Seq in the 
androgen sensitive LNCaP PCa cell line [9], coupled 
to genome-wide mapping data for AR binding sites [3] 
and clinical PCa expression array data [10] to identify an 
androgen-driven mechanism of glycosylation change. This 
mechanism involves a new splice variant of ST6GalNAc1 
which encodes a novel short protein isoform that controls 
PCa cell adhesion. 
RESULTS
ST6GalNAc1 is upregulated in primary prostate 
cancer and is an early and direct target of the AR
We used RNA-Seq to monitor androgen-mediated 
changes in the transcriptome of LNCaP cells treated 
with 10 nM of the synthetic androgen analogue R1881 
(methyltrienolone) for 24 hours. The Cufflinks package 
reported 674 up- and 1834 down- regulated genes (p < 
0.0075, Supplementary Figure 1 and Supplementary 
Tables 2 and 3). The RNA-Seq reads aligned to the 
human genome (hg19) can be visualised for any 
gene using the following link: http://genome-euro.
ucsc.edu/cgi-bin/hgTracks?db=hg19&position=ch
r17%3A74620838-74639920&hgsid=208866799_
IfRA3VMoSbPBVAhT3NJysAg6KahE 
A comparison of RNA-Seq data with our previously 
published exon microarray data [11] showed an 86% 
overlap, with > 4 times more differentially expressed 
genes identified by RNA-Seq (Supplementary Table 4). To 
identify genes of potential clinical interest we compared 
genes up-regulated in response to R1881 with published 
AR binding sites [3] and clinical PCa expression array 
data [10] (GSE35988, downloaded from the NCBI GEO 
data repository). The criteria applied were the presence of 
an AR binding site within 50kb of the transcription start 
site of the gene, significant differential gene expression 
reported in the clinical dataset [10] and evidence of 
androgen-regulated expression in the LNCaP RNA-
Seq data. Three genes fulfilled these stringent selection 
criteria (Figure 1A and Supplementary Tables 5 and 
6). Two of these three overlapping genes already have 
established roles in clinical PCa. These were CAMKK2 
which is an important determinant of central metabolism 
and is over-expressed in PCa [3]; and the ATP-binding 
cassette transporter ABCC4 that is implicated in disease 
progression and resistance of PCa cells to nucleotide-
based chemotherapeutic drugs [12]. Also found within 
this overlapping subgroup was the ST6GalNAc1 gene. 
Both CAMKK2 and ABCC4 are previously known to be 
activated in response to androgens, and using qRT-PCR we 
in PCa cells reduced formation of stable tumours in mice, reduced cell adhesion and 
induced a switch towards a more mesenchymal-like cell phenotype in vitro. ST6GalNAc1 
has a dynamic expression pattern in clinical datasets, being significantly up-regulated in 
primary prostate carcinoma but relatively down-regulated in established metastatic tissue. 
ST6GalNAc1 is frequently upregulated concurrently with another important glycosylation 
enzyme GCNT1 previously associated with prostate cancer progression and implicated in 
Sialyl Lewis X antigen synthesis. Together our data establishes an androgen-dependent 
mechanism for sTn antigen expression in PCa, and are consistent with a general role for 
the androgen receptor in driving important coordinate changes to the glycoproteome 
during PCa progression.
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Figure 1: ST6GalNAc1 is an early and direct target of the AR and is upregulated in primary prostate tumours. A. 
RNA-sequencing was carried out on RNA extracted from LNCaP cells grown in media supplemented with 10% charcoal dextran stripped 
FBS (steroid deplete media, SD) or stimulated with 10nM synthetic androgen analogue methyltrienolone (R1881) for 24 hours (androgens, 
A+). We compared genes up-regulated in response to R1881 with published AR binding sites [3] and clinical PCa expression array data 
[10] (GSE35988, downloaded from the NCBI GEO data repository). The criteria applied were the presence of an AR binding site within 
50kb of the transcription start site of the gene, significant differential gene expression in the clinical dataset [10] (genes over-expressed by 
1.6 fold or more in cancer vs. normal when profiled using an array platform (Agilent-012391 Whole Human Genome Oligo Microarray 
G4112A)), and evidence of androgen-regulated expression in the RNA-Seq data (fold change > 1.6 as reported by the cufflinks package). 
This identified three genes which overlapped between all three data sets, CAMKK2, ABCC4 and ST6GalNAc1. B. We confirmed androgen-
regulation of these genes by real-time PCR (using 3 independent sample sets treated with 10nM R1881 for 24 hours) and identified 
ST6GalNAc1 as a novel androgen regulated gene. C. Real-time PCR analysis of ST6GalNAc1 mRNA from 32 benign samples from patients 
with benign prostatic hyperplasia (BPH) and 17 malignant samples from transurethral resection of the prostate (TURP) samples. D. We 
also analysed RNA from normal and matched PCa tissue from 9 patients obtained by radical prostectomy. E. Real-time PCR analysis of 
ST6GalNAc1 mRNA in LNCaP cells stimulated with 10 nM R1881 (A+) or without (SD) over 24 hours, showed increased expression 
after less than 3 hours of androgen stimulation; a similar pattern is seen for KLK3 (PSA). F. Induction of ST6GalNAc1 is also evident 
in LNCaP cells treated with 0.5 to 100nM of R1881 for 24 hours. Relative ST6GalNAc1 expression was detected by real-time PCR. G. 
Up-regulation of ST6GalNAc1 mRNA in response to treatment with 10 nM R1881 for 24 hours is negated by the AR antagonist 10µM 
Casodex® (bicalutamide) but not by ethanol alone (vehicle). H. Analysis of publically available patient RNA-seq data pre- and post- 
androgen ablation therapy for ST6GalNAc1 shows that following androgen ablation there is a down-regulation of ST6GalNAc1 mRNA for 
all 7 patients tested[63]. I. AR-ChIP in LNCaP cells treated with 10nM R1881 for 24 hours revealed one AR binding sites in close proximity 
to the ST6GalNAc1 gene (for details of the binding sites see Supplementary Figure 2). 
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similarly confirmed strong androgen-dependent induction 
of these ST6GalNAc1 genes (Figure 1B). 
To examine if expression of the ST6GalNAc1 gene 
becomes changed in clinical prostate cancer we carried 
out meta-analysis of 544 prostate tumours using data 
from 7 previously published studies [10, 13-17]. We 
found that 6/7 datasets showed significant up-regulation 
of ST6GalNAc1 mRNA expression in prostate carcinoma 
versus normal prostate tissue (Supplementary Table 7). 
ST6GalNAc1 expression showed an average mean fold 
change of 2.951 (p = 5.18E-7) in 122 primary PCa samples 
studied by Grasso et al. [10], and a mean fold change of 
4.049 (p = 1.99E-6) in samples studied by Varambally et 
al. [17], with ST6GalNAc1 ranked in the top 1% of over-
expressed genes. In order to test the results of this meta-
analysis, we further analysed ST6GalNAc1 expression in 
a panel of clinical PCa samples by qRT-PCR. We found 
ST6GalNAc1 mRNA was significantly up-regulated in 
prostate carcinoma relative to BPH tissue (p = 0.048), 
and in primary prostate tumour tissue relative to matched 
normal tissue from the same patient (p < 0.04) (Figure 
1D).
Induction of ST6GalNAc1 gene expression was 
extremely rapid and could be detected < 3 hours after 
androgen exposure suggesting it is directly regulated 
by the AR. The early expression profile of ST6GalNAc1 
following androgen exposure had similar dynamics to the 
known directly AR-regulated gene KLK3 (Figure 1E). 
Androgen-mediated induction of ST6GalNAc1 expression 
was induced over a range of R1881 concentrations 
consistent with ST6GalNAc1 induction also occurring 
under physiological conditions within the prostate (Figure 
1F), and blocked by treatment with the AR antagonist 
Casodex® (bicalutamide) (Figure 1G). Analysis of 
previously published RNA-Sequencing data from 7 PCa 
patients [63] showed that ST6GalNAc1 gene expression is 
also strongly down-regulated following ADT in all cases 
(Figure 1H), suggesting that ST6GalNAc1 is also regulated 
(either directly or indirectly) by androgens in vivo, and is 
clinically relevant in patients.
Multiple AR binding sites (ARBSs) situated both 
upstream and within the ST6GalNAc1 gene had been 
previously predicted by ChIP-Seq [3]. We confirmed 
direct AR binding in LNCaP cells at an ARBS in close 
proximity to ST6GalNAc1 using ChIP-qPCR (p < 0.004) 
(Figure 1I and Supplementary Figure 2). Induction of 
ST6GalNAc1 mRNA expression in response to androgens 
was further confirmed in the androgen-responsive VCaP 
cell line (Supplementary Figure 2). In VCaP cells, 
which have amplification of the AR [18], we found six 
sites of AR binding within 50Kb of the ST6GalNAc1 
gene (Supplementary Figure 2). Androgen induction of 
ST6GalNAc1 was very specific: no parallel induction of 
the ST6GalNac2-6 genes was observed in response to 
androgen exposure (Supplementary Figure 3).
A novel isoform of ST6GalNAc1 is expressed in 
prostate cells in response to androgen stimulation 
The above data indicated that ST6GalNAc1 gene 
expression is induced by the AR in LNCaP and VCaP 
cells, and reciprocally repressed by ADT in patients 
with PCa. We thus tested if ST6GalNAc1 protein is also 
induced by androgens. Surprisingly, rather than the 
previously described 69KDa full length ST6GalNAc1 
canonical protein isoform, we detected predominant 
androgen-inducible expression of a ~55KDa protein in 
LNCaP cells on western blots, using an antibody specific 
to the C-terminal of the ST6GalNAc1 protein (Figure 2A). 
Expression of this ~55KDa protein isoform was sensitive 
to siRNA-mediated depletion of ST6GalNAc1 (Figure 
2A), and was not induced in androgen treated LNCaP cells 
depleted of the AR (Figure 2B), indicating it is a novel 
androgen regulated isoform of ST6GalNAc1 protein.
Further investigation indicated this novel 55 kDa 
protein isoform is encoded by a novel splice isoform. The 
canonical 69KDa ST6GalNAc1 protein isoform is encoded 
by a splice isoform of mRNA which skips exon 2 (NCBI 
Reference Sequence: NM_018414.4). Closer inspection 
of our RNA-Seq data showed reads mapping to exon 2 
of ST6GalNAc1 following androgen treatment, indicating 
that exon 2 is also specifically included in LNCaP cells in 
response to androgens as well as induction of the entire 
gene (Figure 2C and Supplementary Figure 4). Inclusion 
of ST6GalNAc1 exon 2 leads to an mRNA with a longer 
5′ UTR, that uses an alternative downstream translational 
start codon predicted to encode a 55KDa protein (NCBI 
Reference Sequence: NM_001289107.1). In androgen-
treated LNCaP cells we detected ST6GalNAc1 mRNA both 
with and without exon 2 using RT-PCR (Figure 2D). We 
also detected ST6GalNAc1 exon 2 inclusion in a number 
of other PCa cell lines by RT-PCR (Supplementary Figure 
5A, 5B). 
The novel 55kDa protein isoform of ST6GalNAc1 is 
missing 132 amino acids from the N-terminus, including 
a predicted trans-membrane domain (Figure 2E) and an 
epitope recognised by another α-N-terminal ST6GalNAc1 
antibody (Figure 2F). Using western blots and this α-N-
terminal ST6GalNAc1 antisera, we detected the canonical 
69KDa ST6GalNAc1 protein in LNCaP cells, and found 
that this was also androgen-inducible and sensitive to 
siRNA-mediated depletion of ST6GalNAc1 (Figure 2G). 
Taken together these data show the 69KDa ST6GalNAc1 
protein isoform is also produced in LNCaP cells, but at 
lower levels than the shorter 55KDa isoform, and both 
are androgen inducible, which would be expected since 
they are transcribed from the same promoter. We further 
confirmed the relative sizes of the two ST6GalNAc1 
protein isoforms through detection of over-expressed 
protein with both antibodies (Figure 2H: note these over-
expressed proteins in DU145 cells are fusion proteins, so 
migrate slightly slower than their endogenous counterpart 
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Figure 2: A novel alternative splice isoform of ST6GalNAc1 is expressed in response to androgen stimulation. A. 
Androgen regulation of ST6GalNAc1 in LNCaP cells was confirmed at the protein level by western blot (A, left panels). This revealed 
a band at approximately 55KDa which was not detected in cells grown in the absence of hormone (steroid deplete, SD), but induced by 
treatment with 10 nM of the synthetic androgen R1881 for 24 hours (A+). Depletion of ST6GalNAc1 in androgen stimulated cells using 
siRNA (A, right panels) confirmed the specificity of the band. B. Depletion of AR protein in LNCaP cells by esiRNA shows that when the 
AR is depleted there is no induction of ST6GalNAc1 protein in response to androgens (cells were treated with or without 10nM R1881 
for 48 hours). C. Visualisation of our LNCaP cell RNA-seq reads (see Figure 1 for details) on the UCSC genome browser identified 
a novel isoform of ST6GalNAc1 which includes an additional exon (exon 2). This isoform has a longer 5’ untranslated region and is 
predicted to produce a shorter 55kDa protein which is missing the first 132 amino acids. D. PCR using primers specific to exon 1 and 
3 produced two bands indicating the presence of two ST6GalNAc1 mRNA isoforms (with and without exon 2) in LNCaP cells treated 
with 10nM R1881 for 24 hours. E. Model showing predicted localisation domains in ST6GalNAc1. ST6GalNAc1-short is missing a 
predicted transmembrane localisation domain from amino acids 15-35 (http://www.uniprot.org/uniprot/Q9NSC7). F. The ST6GalNAc1 
antibody used in A. was raised against the C-terminal of the protein, meaning that it will detect both isoforms. An additional antibody to 
the N-terminal of ST6GalNAc1 will not detect the 55kDa ST6GalNAc1-short protein. G. Detection of ST6GalNAc1 using the N-terminal 
antibody confirms that the 69kDa ST6GalNAc1 protein is also expressed, although at presumably at much lower level that the 55kDa 
isoform. Depletion of ST6GalNAc1 using siRNA confirmed the specificity of the band (G, right panels). H. Western blot detection of 
FLAG-tagged over-expressed ST6GalNAc1 and ST6GalNAc1-short by the N- and C-terminal antibodies in DU145 cell lines. As predicted 
the N-terminal antibody does not detect ST6GalNAc1-short but does detect full length protein (H, left panel, lanes 3 and 4 respectively). 
The C-terminal antibody detects both isoforms (H, right panel, lanes 3 and 4 respectively). I. ST6GalNAc1-short is detected in a panel 
of 5 PCa samples by real-time PCR (using primers specific to exon 2), and at the protein level by western blot. LNCaP cells grown in the 
presence of 10 nM of the synthetic androgen R1881 for 48 hours were used as a positive control. 
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Figure 3: The sialyl-Tn antigen is androgen-regulated in LNCaP cells. Analysis of glycosylation in LNCaP cells grown in the 
presence or absence of androgens (10nM R1881) for 72 hours by immunofluorescence. Androgen-mediated up-regulation of sTn antigen 
(formed by ST6GalNAc1 catalysed sialylation of GalNAc residues) is observed using two different antibodies A., B. Induction of sTn by 
androgens is inhibited by the presence of 10μm Casodex® (bicalutamide) C. and by esiRNA mediated depletion of ST6GalNAc1 D.. Bar 
is 10 μm. 
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proteins). 
Analysis of publically available RNA-Seq data [19] 
show that ST6GalNAc1 exon 2 is detected in both clinical 
prostate cancer and in a number of additional cancers, 
particularly lung cancer (Supplementary Figure 5C). 
Interrogation of the Taylor et al. dataset [16] revealed that 
in clinical PCa samples ST6GalNAc1 exon 2 is expressed 
at similar levels to other exons in the ST6GalNAc1 
gene (Supplementary Figure 6), suggesting that it is 
also the short isoform of ST6GalNAc1 that is expressed 
in PCa tumours. Confirming that this short protein is 
the major ST6GalNAc1 protein isoform expressed in 
clinical prostate cancer, the 55KDa ST6GalNAc1 protein 
isoform was also detected in androgen-treated VCaP cells 
(Supplementary Figure 2), and in clinical prostate samples 
by western blot analysis in 5 out of 5 tissue lysates (Figure 
2I).
Androgen exposure induces expression of the sTn 
antigen in PCa cells
Given the strong induction of ST6GalNAc1 in 
response to androgen exposure, we tested if the sTn 
antigen might also be androgen-regulated. Consistent 
with this prediction, two independent monoclonal 
antibodies specific to sTn antigen detected androgen-
activated expression of this cancer-associated antigen 
in LNCaP cells (Figure 3A, 3B). Induction of the sTn 
antigen by androgens in LNCaP cells was inhibited by 
the AR antagonist Casodex® (bicalutamide) (Figure 3C), 
by esiRNA mediated depletion of ST6GalNAc1 (Figure 
3D), and by esiRNA mediated depletion of the AR 
(Supplementary Figure 7) indicating a direct mechanism 
of induction. Induction of sTn antigen by androgen 
treatment was also evident in VCaP cells (Supplementary 
Figure 2).
The short isoform of ST6GalNAc1 functions as a 
sialyltransferase in PCa cells and induces sTn
While the 69KDa ST6GalNAc1 protein isoform is 
known to function as a sialyltransferase [7], no function 
had been assigned to this shorter protein isoform. To 
evaluate the relative activity of the 55KDa isoform, 
FLAG-tagged full-length ST6GalNAc1 and ST6GalNAc1-
short were expressed in Flp-In HEK293 cells and purified 
by immunoprecipitation. Protein purification was 
confirmed by western blot using antibodies against the 
FLAG antigen (Figure 4A, upper panel). Empty pcDNA5-
FLAG vector was used as a control (lane 1). The activity 
of the immunoprecipitated proteins were assayed in a 
sialyltransferase assay. Despite missing the N-terminal 
132 amino acids, the shorter isoform of ST6GalNAc1 
protein still functioned as a sialyltransferase enzyme at 
similar levels to the full-length isoform (Figure 4A, lower 
panel). 
To enable us to investigate the relative activities of 
the short and long ST6GalNAc1 protein isoforms in the 
absence of competing endogenous protein, we carried out 
analysis in DU145 cells (RT-qPCR analysis indicated low 
endogenous levels of ST6GalNAc1 expression in this cell 
line) by creating stable cell lines over-expressing each 
isoform (Figure 4B). Consistent with either ST6GalNAc1 
protein isoform being able to transfer a sialic acid in ɑ2-6 
linkage onto the Tn antigen, we found that stable cell lines 
expressing full length ST6GalNAc1 or ST6GalNAc1-short 
each had increased levels of the sTn antigen (Figure 4C). 
We also obtained identical results in PC3 cells, where 
inducible over-expression of both ST6GalNAc1 isoforms 
increased sTn antigen levels (Supplementary Figure 8).
Taken together, the above data demonstrate that the 
newly identified short isoform of ST6GalNAc1 is active 
as a sialyltransferase, and capable of synthesising the 
cancer-associated sTn antigen similarly to the previously 
characterised 69KDa ST6GalNAc1 protein isoform. 
Sub-cellular localisation experiments showed that 
endogenous ST6GalNAc1 protein (which our western 
data show will be predominantly the short isoform) is 
distributed throughout the cytoplasm and specifically in 
the centrosome in LNCaP cells (Supplementary Figure 9).
Expression of ST6GalNAc1 in PCa cells reduces 
adhesion, increases motility and promotes a 
transition towards a mesenchymal like phenotype
Since expression of ST6GalNAc1 increases tumour 
mass in breast and colon cancer [20, 21], we analysed 
the effect of ST6GalNAc1 on prostate tumourigenesis 
using in vivo models. DU145 cells stably transfected 
with either empty vector control or ST6GalNAc1-short 
(5 x 106 cells) were injected subcutaneously into nude 
mice (n=6 mice per group), and the resulting tumours 
measured twice weekly using a caliper. Tumours grew in 
5/6 mice in the control group and 6/6 in the experimental 
one. Surprisingly, over-expression of ST6GalNAc1-short 
resulted in a very clear decrease in tumour growth (p< 
0.0001, two-way ANOVA) (Figure 5A). 
Since ST6GalNAc1 expression has been shown 
to increase establishment of metastases in breast and 
colon cancer [20, 21], we next examined tumour cell 
dissemination by injecting DU145 cells tagged with 
Gaussia luciferase (G-Luc) intravenously (Supplementary 
Figure 10A). This allows imaging of metastatic foci 
in vivo but also has the advantage over other luciferase 
species to be secreted and therefore provide means to 
monitor disseminated tumour cells by measuring its levels 
in blood and /or urine [22].  One million cells were injected 
intravenously (n=6 for each control and experimental 
group). Whole-body imaging following coelenterazine 
intraperitoneal administration was performed twice 
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Figure 4: The short isoform of ST6GalNAc1 functions as a sialyltransferase in PCa cells and induces expression of 
sTn. A. FLAG-tagged long and short isoforms of ST6GalNacI were purified from Flp-In HEK293 cells by immunoprecipitation. Isolation 
was confirmed by western blot (A, upper panel). The purified proteins were then used directly in an in vitro sialylation assay (A, lower 
panel). Phosphate standard (R&D Systems EA002) was used as a positive control and to produce a standard curve. Despite missing the 
first 132 amino acids ST6GalNAc1-short is still able to function as a sialyltransferase in vitro. B. Detection of ST6GalNAc1 by real-time 
PCR and western blot in DU145 cells stably transfected with either empty vector (lane 1), full length FLAG-tagged ST6GalNAc1 (lane 2), 
or FLAG-tagged ST6GalNAc1-short (lane 3). Detection of bands at just above 55kDa and 69kDa by western blot confirm the successful 
creation of stable cell lines expressing both isoforms. C. Immunofluorescence detection of the sTn antigen using the B72.3 antibody in 
DU145 cells stably expressing either a control empty vector, full length ST6GalNAc1 or ST6GalNAc1-short. There is increased detection 
of sTn in cells transfected with both isoforms of ST6GalNAc1. Images are representative of 3 independent experimental repeats.
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Figure 5: Expression of ST6GalNAc1 in PCa cells reduces adhesion, increases mobility and promotes transition 
towards a mesenchymal phenotype. A. Tumour growth curves comparing cells transfected with either empty vector or ST6GalNAc1 
(p<0.0001, two-way ANOVA). Right panel - mice in both groups - black circles show tumours contours. Adhesion B. and migration C. 
assays using our DU145 stable cell lines. There is a significant decrease in adhesion in cells expressing ST6GalNAc1-short for uncoated 
plates and for plates coated with collagen I or fibronectin (p < 0.001). Cells stably transfected with ST6GalNAc1-short also have an 
increased rate of migration (p < 0.003). Representative images used for the analysis are shown in Supplementary Figure 8. D. Real time 
PCR analysis of DU145 cells over-expressing ST6GalNAc1 indicates significant changes in the mRNA expression of key markers of 
EMT. These included a reduction of E-cadherin expression, and an increase in N-cadherin expression, as well as an increase in slug, 
β-microglobulin, vimentin and β-catenin. The changes in E-cadherin, N-cadherin and Vimentin expression were confirmed at the protein 
level by western blot E.. Images are representative of 3 independent experimental repeats.
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weekly. Over the course of 12-weeks follow-up none of 
the mice developed clear metastatic foci (representative 
example in Supplementary Figure 10B). Monitoring of 
urine and blood in these mice showed G-Luc levels above 
background (from disseminated cancer cells), however 
no difference was observed between the control and 
ST6GalNAc1-short overexpressing cells – for an example 
see G-Luc quantification in blood at the end-point of 
the experiment (Supplementary Figure 10C). Our data 
suggests that unlike in breast and colon cancer, over-
expression of ST6GalNAc1 in PCa cells reduces tumour 
growth and does not affect metastasis. This data would 
be consistent with a decrease in cell adhesion that would 
hamper the formation of stable tumour masses.
To investigate how expression of ST6GalNAc1 
might result in a decrease in tumour mass, we analysed 
adhesion and mobility properties of the stably transfected 
DU145 cells. Over-expression of either isoform of 
ST6GalNAc1 protein significantly reduced cell adhesion 
on uncoated plates, and also on plates coated with 
collagen I and fibronectin (p<0.01) (Figure 5B). We also 
detected an increased rate of cell migration (p<0.04) 
for cells over-expressing both isoforms (Figure 5C and 
Supplementary Figure 11A). To determine whether this 
observed phenotypic change was occurring as a result 
of cellular reprogramming of PCa epithelial cells to a 
more mesenchymal-like phenotype (a process termed 
epithelial-mesenchymal transition, or EMT), we examined 
the expression of key EMT markers in our stable cell 
lines. RT-qPCR analysis showed that DU145 cells 
stably over-expressing either isoform of ST6GalNAc1 
protein switched from E-cadherin to N-cadherin gene 
expression, and also increased expression of Vimentin, 
Snail, β-microglobulin and β-catenin (Figure 5D). Loss of 
E-cadherin and an increase in N-cadherin and vimentin 
protein expression was confirmed by western blotting 
(Figure 5E). 
The above data indicate stable over-expression of 
ST6GalNAc1 induces a switch to a more mesenchymal 
like pattern of gene expression in PCa cells. This predicts 
that similar changes should also occur in LNCaP cells in 
response to androgen exposure. Consistent with this, and 
in agreement with the findings of others [23] we found that 
culture of LNCaP cells in androgens for 72 hours similarly 
resulted  in a shift towards an more mesenchymal-like 
pattern of gene expression (Supplementary Table 8). We 
also observed a significant reduction in cell adhesion 
in LNCaP cells treated with androgens for 72 hours 
(p=0.015), and this effect was blocked in cells treated with 
ST6GalNAc1 esiRNA (Supplementary Figure 11B). Co- 
expression analysis of ST6GalNAc1 and EMT markers 
in the Taylor et al. study [16] also revealed a tendency 
Figure 6: Clinical expression data indicate a changing pattern of ST6GalNac1 expression between primary and 
metastatic tumours. Expression of ST6GalNAc1 mRNA in clinical PCa samples measured by A. Taylor et al. [16] and B. Grasso et al. 
[10]. In both studies the expression of ST6GalNAc1 is significantly increased in primary prostate carcinoma, but significantly decreased in 
metastatic tissue. Data was generated using Oncomine. C. Analysis of data generated by Taylor et al. [16] for co-occurrence of ST6GalNAc1 
and other glycosylating enzyme mRNA (Z scores v normal +/- 1.6). ST6GalNAc1 was significantly co-occurrent with GCNT1 (p = 0.003) 
(p values were derived from exact Fisher tests).
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towards co-occurrence for expression of ST6GalNAc1 and 
genes related to EMT (Supplementary Table 9). 
Clinical expression data indicate a changing 
pattern of ST6GalNAc1 expression between 
primary and metastatic tumours
The data presented above suggests that expression 
of ST6GalNAc1 mRNA is significantly up-regulated in 
primary prostate tumours relative to normal prostate 
gland (Figure 1 and in Supplementary Table 7). Closer 
inspection of both the Grasso and Taylor datasets 
revealed a dynamic switch in the expression pattern of 
ST6GalNAc1. A comparison of ST6GalNAc1 expression 
in primary and metastatic prostate cancer shows that 
ST6GalNAc1 expression strikingly decreases in metastatic 
PCa cells (Figure 6A, 6B). These results are in agreement 
with the findings of Varambally [17], where ST6GalNAc1 
was found to be 4.43 fold over-expressed in localised 
prostate cancer versus benign tissue (p = 2.36E-006), but 
-5.9 fold under-expressed (p = 1.85E-007) in metastatic 
disease versus localised cancer; and are also consistent 
with a recent study where expression of ST6GalNAc1 was 
found to be 2.67 fold reduced in the progression to CRPCa 
(p = 1.55E13) [24].
 We also analysed whether expression of 
ST6GalNAc1 in clinical data correlates with expression of 
a variety of glycoprotein synthetic enzymes implicated in 
PCa progression [25-29]. A recent meta-analysis of clinical 
PCa gene expression data identified a novel discriminatory 
signature enriched for 4 glycosylating enzymes 
ST6GalNAc1: glucosaminyl (N-acetyl) transferase 1, core 
2 (GCNT1), UDP N-acetylglucosamine pyrophosphorylase 
1 (UAP1) and beta-1,3-glucuronyltransferase 1 (B3GAT1) 
[25]. Analysis of the Taylor et al. dataset [16] revealed 
that up -regulation of ST6GalNAc1 is significantly co-
occurrent with that of GCNT1 (p = 0.003). We also found 
a tendency for co-occurrence for ST6GalNAc1 and UAP1 
(Figure 6C). Hence, 95.7% (67 out of 70) of primary 
prostate tumours with up-regulated ST6GalNAc1 mRNA 
also had up-regulation of at least one other glycosylating 
enzyme (Z score v normal +/- 1.6). These findings strongly 
suggest that the in vivo impact of gene ST6GalNAc1 
expression in PCa will be influenced by its interplay with 
other glycosylating enzymes.
DISCUSSION
Here we show that expression of the sialyltransferase 
enzyme ST6GalNAc1 is directly activated by androgens 
in prostate cancer cells. ST6GalNAc1 catalyses synthesis 
of the cancer-associated sialyl-Tn antigen (sTn), which is 
expressed in a variety of carcinomas and is correlated with 
metastasis and poor prognosis in patients [30-33]. Our 
results show for the first time that expression of sTn is 
induced by androgens in prostate cancer cells and that this 
is mediated by ST6GalNAc1. These results are important, 
as expression of sTn has been detected in up to half of 
high grade prostate tumours [30, 34]. 
Surprisingly, we find that rather than the canonical 
69 KDa isoform of ST6GalNAc1, a novel ~55KDa 
protein isoform of the ST6GalNAc1 protein isoform is 
instead induced by androgens in prostate cancer cell lines 
in vitro, and also expressed in clinical prostate tissue. 
This shorter 55 KDa isoform is thus the major expressed 
ST6GalNAc1 isoform in the prostate. To the best of our 
knowledge this is the first identification of this shorter 
ST6GalNAc1protein isoform, which is made from an 
alternatively spliced mRNA. The canonical 69KDa 
ST6GalNAc1 protein isoform is the major previously 
reported isoform in breast and colon cancers where it has 
been well-studied [7, 21, 31, 35-37]. Despite missing some 
N-terminal peptide sequence, we find the ~55KDa protein 
isoform of the ST6GalNAc1 still functions enzymatically 
as a sialyltransferase in PCa cells and is capable of 
synthesising the sTn antigen. 
We find that expression of ST6GalNAc1 in PCa cells 
changes gene expression towards a more mesenchymal-
like pattern, increases cell mobility and decreases 
cell adhesion. A switch towards a more mesenchymal 
phenotype has previously been shown to be important for 
the progress of PCa [38-41], and there is growing evidence 
for a close link between altered glycosylation and changes 
in EMT [42-45]. The EMT transition is thought to have a 
role in the dissemination of tumour cells, however, recent 
work has suggested that EMT reversion may be required 
for metastatic outgrowth [46, 47]. Meta-analysis of clinical 
RNA-Seq datasets show that although ST6GalNAc1 
expression is up-regulated in primary prostate carcinoma, 
expression is relatively reduced in metastatic prostate 
tissue. The patterns of ST6GalNAc1 expression that we 
report here are thus consistent with a transient role for 
ST6GalNAc1 in PCa progression. Our data suggests the 
increase in ST6GalNAc1 expression in the primary tumour 
under the influence of androgens may be the result and not 
the cause for the initial tumour evolution; however this is 
a necessary step for tumour cells to be able to evolve to 
the next level in progression - acquiring a mesenchymal, 
migratory phenotype. It is interesting to speculate that 
despite ST6GalNAc1 being significantly upregulated in 
primary prostate tissue where it facilitates cell migration 
from the primary tumour, a reduction in ST6GalNAc1 may 
be required to form stable metastases. 
Expression of ST6GalNAc1 in gastric and breast 
cancer cell lines also leads to reduced cell adhesion and 
increased cell motility, similar to what we observe in the 
prostate [20, 21, 31, 48, 49]. However, in breast and colon 
cancer over-expression of ST6GalNAc1 has been shown 
to increase both tumour growth and metastatic ability [20, 
21], which was not seen here in PCa cells. Meta-analysis of 
ST6GalNAc1 expression in colon and breast cancer tissue 
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versus normal tissue shows significant down-regulation 
in 6/8 datasets for primary colon cancer (Supplementary 
Table 7B), and in 4/8 datasets for primary breast cancer 
(Supplementary Table 7C), the opposite of what we see 
in PCa. Expression of ST6GalNAc1 in gastric and breast 
cancer cell lines induces the sTn antigen and leads to 
reduced cell adhesion and increased cell motility [20, 21, 
31, 48, 49], similar to what we observe in the prostate. 
Together these data suggest the roles of ST6GalNAc1 will 
need to be individually analysed in different cancers.
The androgen-induced changes in sTn expression 
we detect here most likely occur against a background 
of androgen-induced changes in cellular glycosylation. 
There is growing evidence linking changes in the 
glycoproteome to PCa progression [25-29, 50, 51]. UAP1 
and GCNT1 have been shown to be upregulated in PCa 
[26, 27, 52], and the amino-sugar conjugate, O-linked 
N-acetylglucosamine (O-GlcNAc) is significantly elevated 
in prostate cancer tissue [29, 53]. Previous work has 
shown that the hexosamine biosynthetic pathway enzymes 
UAP1 and GFPT1 are directly regulated by the AR in PCa 
cells [27]. Our finding that the O-linked glycosylating 
enzyme ST6GalNAc1 is androgen-regulated provides 
further evidence for a direct link between the AR and the 
glycoproteome in prostate cancer cells, and also suggests 
that it will be important to understand how these changes 
function co-ordinately rather than in isolation to modify 
the cellular behaviour of cancer cells.
MATERIALS AND METHODS
RNA-seq and analysis
RNA was prepared for sequencing using a RNA 
Easy Kit (Qiagen 74104) and treated with DNase 1 
(Ambion). RNA-sequencing was carried out using 
Illumina HiSeq by the Norwegian Sequencing Centre 
(http://www.sequencing.uio.no/) and analysed as 
described previously [54]. Reference files for the human 
genome (UCSC build hg19) were downloaded from the 
Cufflinks pages: http://cufflinks.cbcb.umd.edu/igenomes.
html. UCSC-hg19 package from June 2012 was used. 
The software versions used for the analysis were TopHat 
v1.4.1, SAM tools v0.1.18 (r982:295), bowtie v0.12.8 
(64-bit) and cufflinks v1.3.0 (linked against Boost 
v104000). Nature protocol published under doi:10.1038/
nprot.2012.016 was followed. For steps 1-5, no parameters 
(except for paths to input/output files) were altered. In 
step 15, additional switches -s, -R, and -C were used 
when running cuffcompare. Steps 16-18 (extraction of 
significant results) were performed on the command line. 
The complete command list for the individual steps is 
given in Supplementary Methods 1. 
Antibodies
The following antibodies were used: anti-
ST6GalNAc1 C-term (Rb pAb, 15363-1, Proteintech), 
anti- ST6GalNAc1 N-term (Rb pAb, HPA014975, Sigma-
Aldrich), anti-Sialyl Tn (Ms mAb, Abcam 115957), 
anti-CDK5RAP2 (Rb pAb, ab86340, Abcam), γ-tubulin 
[GTU-88] (Ms mAb, ab11316, Abcam), α-tubulin (Ms 
mAB, T6199, Sigma), Lectin PNA [Alexa Fluor® 488 
conjugated] (L21409, Life Technologies), anti-actin (Rb 
pAb, A2668, Sigma), anti-FLAG mouse monoclonal 
antibody (F3165, Sigma), normal rabbit IgG (711-035-
152 Jackson labs) and normal mouse IgG (715-036-150 
Jackson labs). Anti-sialyl Tn B72.3 (mAb) was prepared 
as follows: The B72.3 hybridoma cell line [55] was 
obtained from ATCC. The hybridoma cells were adapted 
to serum-free medium (Hybridoma SFM, Invitrogen). 
B72.3 mAb was affinity-purified from the tissue culture 
supernatant using the AbSelect mouse TCS purification 
system (Innova Biosciences). 
DNA constructs
Full length ST6GalNAc1 cloned into pcDNA3.1+ 
(V790-20, Invitrogen) was a kind gift from Hidenori 
Ozaki (AIST, Japan). This was then cloned into pX3FLAG 
CMV 10 (E7658, Sigma) using EcoRI and XbaI and into 
pcDNA5-FLAG (V6520-20, Invitrogen) using BamH1 
and XhoI. ST6GalNAc1 short isoform was cloned into 
pX3FLAG CMV 10 (E7658, Sigma) using EcoR1 and 
XbaI and into pcDNA5-FLAG (V6520-20, Invitrogen) 
using BamH1 and XhoI. Full length ST6GalNAc1-GFP 
and ST6GalNAc1 short-GFP were cloned into pcDNA3.1+ 
using EcoR1 and XhoI. 
Cell culture
Cell culture was as described previously [11, 56, 
57]. All cells were grown at 37°C in 5% CO2. LNCaP 
cells (CRL-1740, ATCC) were maintained in RPMI-
1640 with L-Glutamine (PAA Laboratories, R15-802) 
supplemented with 10% Fetal Bovine Serum (FBS) (PAA 
Laboratories, A15-101). For androgen treatment of cells, 
medium was supplemented with 10% dextran charcoal 
stripped FBS (PAA Laboratories, A15-119) to produce a 
steroid-deplete medium. Following culture for 72 hours, 
10 nM synthetic androgen analogue methyltrienolone 
(R1881) (Perkin-Elmer, NLP005005MG) was added 
(Androgen +) or absent (Steroid deplete) for the times 
indicated. Where indicated, LNCaP cells were pre-
treated with 10 μm bicalutamide (Casodex, AstraZeneca) 
or ethanol (vehicle) for 2 hours prior to addition of 
10 nM R1881 for the times indicated. VCaP (ATCC® 
CRL-2876), PC-3 (CRL-1435, ATCC), PC-3M [58], 
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CWR22Rv1 (CRL-2505, ATCC), DU145 (HTB-81, 
ATCC), and BPH-1 cells [59] were maintained in RPMI-
1640 with L-Glutamine supplemented with 10% FBS. 
LNCaP-AI and LNCaP-cdxR were derived from LNCaP 
parental cells and maintained as previously described 
[60, 61]. Transient transfections of GFP-tagged proteins 
were carried out using Lipofectamine 2000 (11668-027, 
Invitrogen). Stable DU145 cell lines expressing full 
length ST6GalNAc1 and ST6GalNAc1-short and were 
generated using DNA constructs cloned into pX3FLAG 
CMV 10 (E7658, Sigma). Cells were transfected using 
Lipofectamine 2000 followed by selection with 300µg/
ml Geneticin (Invitrogen, 10131019) (reduced to 150µg/
ml following the death of untransfected cells) for at least 
four weeks. Flp-In™-293 cells (R750-07, Invitrogen) 
were maintained in DMEM GlutaMax (Invitrogen, 10566-
040), supplemented with 10% FBS (PAA Laboratories, 
A15-101) and stable cell lines generated using the Flp-
In T-Rex Core Kit (K6500-01, Invitrogen) according to 
the manufacturer’s instructions (DNA constructs were 
cloned into pcDNA5-FLAG (V6520-20, Invitrogen)). 
Protein expression was induced using 1 µg/ml tetracycline 
(T7660, Sigma) for 72 hours. PC3 inducible cell lines 
were created using the T-REx™ System according to the 
manufacturer’s instructions (Invitogen, K102001), and 
induced with tetracycline as above.
ChIP
Chromatin of LNCaP and VCaP cells was 
immunoprecipitated as previously described [62] using AR 
antibody (N-20X, Santa Cruz). Levels of ChIP enrichment 
were determined by SYBR green quantitative PCR. Six 
previously reported [3] AR binding sites both upstream 
and at ST6GalNAc1 were assessed for AR enrichments. 
All primer sequences are listed in Supplementary Table 1. 
Clinical Samples
Our study made use of RNA from 32 benign samples 
from patients with benign prostatic hyperplasia (BPH) and 
17 malignant samples from transurethral resection of the 
prostate (TURP) samples. Malignant status and Gleason 
score were obtained for these patients by histological 
analysis. We also analysed normal and matched PCa tissue 
from 9 patients obtained by radical prostatectomy. The 
samples were obtained with ethical approval through the 
Exeter NIHR Clinical Research Facility tissue bank (Ref: 
STB20). We also examined RNA and protein lysates from 
five clinical PCa tissues. For the use of these samples, full 
ethical approval was obtained from the Northumberland, 
Tyne and Wear NHS Strategic Health Authority Local 
Research Ethics Committee (Ref: 2003/11). Written 
informed consent for the use of surgically obtained tissue 
was provided by all patients.
RT-qPCR
Cells were harvested and total RNA extracted 
using TRIzol (Invitrogen, 15596-026) according to 
manufacturer’s instructions. RNA was treated with 
DNase 1 (Ambion) and cDNA was generated by reverse 
transcription of 1µg of total RNA using the Superscript 
VILO cDNA synthesis kit (Invitrogen, 11754-050). 
Quantitative PCR (qPCR) (Applied Biosystems 7900HT) 
was performed in triplicate on cDNA using SYBR® Green 
PCR Master Mix (Invitrogen, 4309155). Samples were 
normalised using the average of three reference genes, 
GAPDH, β -tubulin and actin. All primer sequences are 
listed in Supplementary Table 1.
siRNA
Knockdown of ST6GalNAc1 was carried out using 
a pre-designed silencer select siRNA (Ambion 4392420) 
and further confirmed using ST6GalNAc1 esiRNA from 
Sigma-Aldrich (EHU133871). Scrambled silencer select 
siRNA was used as a control (Ambion). AR esiRNA was 
obtained from Sigma-Aldrich (EHU025951).
Sialyltransferase assay
FLAG-tagged ST6GalNAc1 full length and 
ST6GalNAc1-short were immunoprecipitated from Flp-
In™-293 cell lysates using EZview Red ANTI-FLAG 
M2 Affinity gel (Sigma F2426). Sialyltransferase assays 
were performed using the Sialyltransferase Activity Kit 
(R&D Systems EA002) according to the manufacturer’s 
instructions using 25nmol of CMP-Neu5Ac (Sigma), 
0.5mg asialofetuin (Sigma) and 50ng of Coupling 
Phosphatise 2 for 20 minutes at 37°C. Phosphate Standard 
(Part 895408) was used as a positive control and to 
produce a standard curve. 
Adhesion assays
Coated plates were purchased from R&D 
systems. Cells were labelled with 5µM Calcein-AM 
(BD Biosciences). 50,000 cells per well were allowed 
to adhere for two hours, washed 4 times with PBS, and 
the absorbance measured at 485/538nm. The percentage 
adhesion was then calculated by comparing with an 
identical unwashed plate.
Migration assay
Migration assays were carried out using an OrisTM 
96 well Cell Migration Assay (Platypus Technologies 
CMA1.101) using 100,000 cells per well. Cells were 
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labelled with Calein AM and allowed to adhere for 4 
hours, before removal of the seeding stoppers. Migration 
of cells into the centre of each well after 15 hours was 
measured using ImageJ.
In vivo tumour growth and metastasis assays
DU145 cell stably transfected with either empty 
vector control or ST6GalNAc1-short were injected 
subcutaneously in nude mice (5 x 106 for each mouse, 
n= 6 mice in each group). Once tumours became visible 
their width and length was measured twice weekly using 
a caliper. When the first tumour reached the maximum 
allowed size under the UK Home Office project licence 
(12 mm in any diameter) all mice were culled. Tumour 
volumes were calculated using the formula: [length x 
width x (length+width)/2]. 
For metastasis experiments, cells were transduced 
with a lentivirus expressing Gaussia luciferase 
(GeneCopoeia LPP-MGLUC-LV105-025) and selected 
using puromycin (1 ug/ml). Luciferase was detected 
using the BioLux® Gaussia Luciferase Assay Kit (NEB, 
E3300S) according to the manufacturer’s instructions, 
and normalised to the relative cell number for each cell 
line. One million cells were administered intravenously 
by retroorbital injection. To assess metastatic spread, 
mice were imaged twice weekly using a Xenogen in vivo 
imaging device following intraperitoneal injections with 
200 microliters coelenterazine (RediJect, Perkin Elmer). 
For measuring levels of Gaussia luciferase in urine or 
blood, 10 microliters of urine was collected directly 
from urethral openings. Blood was collected by pricking 
the tail-vein and immediately dispensing into an EDTA-
coated tube. Both fluids were pipetted into a 96-well plate, 
mixed with 100 microliters coelenterazine and imaged in 
the Xenogen devide sequentially at 5, 10, 15 minutes; the 
peak signal (at 10 minutes) was quantified.
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